Home/ Stocks/ GOVX

GeoVax Labs, Inc. New

GOVX XNAS

$0.16 -0.01 (-4.37%) ▼ 15-min delayed

Open

$0.16

High

$0.16

Low

$0.14

Volume

370.9K

Market Cap

$1.44M

About GeoVax Labs, Inc. New

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 19 Website →

Related Market News

No specific coverage for GOVX yet. Check out our latest market news or earnings calendar.

Get GOVX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on GeoVax Labs, Inc. New.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.